Literature DB >> 11268474

Serum tetranectin and CA125 in endometrial adenocarcinoma.

M S Lundstrøm1, C K Høgdall, A L Nielsen, H C Nyholm.   

Abstract

BACKGROUND: CA125 and tetranectin (TN) are prognostic markers in ovarian cancer. This study examines the values of these markers in endometrial cancer.
MATERIALS AND METHODS: TN and CA125 were determined preoperatively in 99 patients with primary endometrioid adenocarcinoma and evaluated in relation to tumor grade, stage and cancer survival.
RESULTS: The CA125 levels correlated significantly with tumor stage. Dichotomized according to a cut-off level of 35 U/ml, CA125 significantly correlated with cancer death. Multivariate regression analysis of cancer survival time showed that CA125 > 35 U/ml was not an independent factor when stage was introduced. TN levels were within the normal range in all patients and did not show any association with tumor grade, stage or survival.
CONCLUSIONS: The study confirmed the role of CA125 as a prognostic factor in endometrial cancer and may be of aid in pointing out patients at high risk, whereas tetranectin did not show any prognostic effect.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11268474

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers.

Authors:  Cynthia Kuk; Vathany Kulasingam; C Geeth Gunawardana; Chris R Smith; Ihor Batruch; Eleftherios P Diamandis
Journal:  Mol Cell Proteomics       Date:  2008-12-01       Impact factor: 5.911

2.  Aberrant tetranectin expression in human breast carcinomas as a predictor of survival.

Authors:  P Obrist; G Spizzo; C Ensinger; D Fong; T Brunhuber; G Schäfer; M Varga; R Margreiter; A Amberger; G Gastl; M Christiansen
Journal:  J Clin Pathol       Date:  2004-04       Impact factor: 3.411

3.  CLEC3B is downregulated and inhibits proliferation in clear cell renal cell carcinoma.

Authors:  Jian Liu; Zhe Liu; Qun Liu; Lina Li; Xiaona Fan; Tao Wen; Guangyu An
Journal:  Oncol Rep       Date:  2018-07-23       Impact factor: 3.906

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.